Novel multisample scheme for inferring phylogenetic markers from whole genome tumor profiles

IEEE/ACM Trans Comput Biol Bioinform. 2013 Nov-Dec;10(6):1422-31. doi: 10.1109/TCBB.2013.33.

Abstract

Computational cancer phylogenetics seeks to enumerate the temporal sequences of aberrations in tumor evolution, thereby delineating the evolution of possible tumor progression pathways, molecular subtypes, and mechanisms of action. We previously developed a pipeline for constructing phylogenies describing evolution between major recurring cell types computationally inferred from whole-genome tumor profiles. The accuracy and detail of the phylogenies, however, depend on the identification of accurate, high-resolution molecular markers of progression, i.e., reproducible regions of aberration that robustly differentiate different subtypes and stages of progression. Here, we present a novel hidden Markov model (HMM) scheme for the problem of inferring such phylogenetically significant markers through joint segmentation and calling of multisample tumor data. Our method classifies sets of genome-wide DNA copy number measurements into a partitioning of samples into normal (diploid) or amplified at each probe. It differs from other similar HMM methods in its design specifically for the needs of tumor phylogenetics, by seeking to identify robust markers of progression conserved across a set of copy number profiles. We show an analysis of our method in comparison to other methods on both synthetic and real tumor data, which confirms its effectiveness for tumor phylogeny inference and suggests avenues for future advances.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Algorithms
  • Biomarkers, Tumor
  • Computational Biology / methods*
  • Computer Simulation
  • DNA / analysis
  • Evolution, Molecular
  • Gene Dosage
  • Genome, Human*
  • Humans
  • Likelihood Functions
  • Markov Chains
  • Neoplasms / genetics*
  • Neoplasms / metabolism
  • Phylogeny
  • Polymorphism, Single Nucleotide
  • Probability
  • Software

Substances

  • Biomarkers, Tumor
  • DNA